Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy
Hirotaka Kimura, Satoshi Eguchi, Junko Sasaki, Keiji Kuba, Hiroki Nakanishi, Shunsuke Takasuga, Masakazu Yamazaki, Akiteru Goto, Hiroyuki Watanabe, Hiroshi Itoh, Yumiko Imai, Akira Suzuki, Noboru Mizushima, Takehiko Sasaki
Hirotaka Kimura, Satoshi Eguchi, Junko Sasaki, Keiji Kuba, Hiroki Nakanishi, Shunsuke Takasuga, Masakazu Yamazaki, Akiteru Goto, Hiroyuki Watanabe, Hiroshi Itoh, Yumiko Imai, Akira Suzuki, Noboru Mizushima, Takehiko Sasaki
View: Text | PDF
Research Article Cardiology Cell biology

Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy

  • Text
  • PDF
Abstract

Hypertrophic cardiomyopathy (HCM) is a common heart disease with a prevalence of 1 in 500 in the general population. Several mutations in genes encoding cardiac proteins have been found in HCM patients, but these changes do not predict occurrence or prognosis and the molecular mechanisms underlying HCM remain largely elusive. Here we show that cardiac expression of vacuolar protein sorting 34 (Vps34) is reduced in a subset of HCM patients. In a mouse model, muscle-specific loss of Vps34 led to HCM-like manifestations and sudden death. Vps34-deficient hearts exhibited abnormal histopathologies, including myofibrillar disarray and aggregates containing αB-crystallin (CryAB). These features result from a block in the ESCRT-mediated proteolysis that normally degrades K63-polyubiquitinated CryAB. CryAB deposition was also found in myocardial specimens from a subset of HCM patients whose hearts showed decreased Vps34. Our results identify disruption of the previously unknown Vps34-CryAB axis as a potentially novel etiology of HCM.

Authors

Hirotaka Kimura, Satoshi Eguchi, Junko Sasaki, Keiji Kuba, Hiroki Nakanishi, Shunsuke Takasuga, Masakazu Yamazaki, Akiteru Goto, Hiroyuki Watanabe, Hiroshi Itoh, Yumiko Imai, Akira Suzuki, Noboru Mizushima, Takehiko Sasaki

×

Figure 2

Vps34-deficient mice develop hypertrophic cardiomyopathy–like cardiomyopathy.

Options: View larger image (or click on image) Download as PowerPoint
Vps34-deficient mice develop hypertrophic cardiomyopathy–like cardiomyop...
(A) Immunofluorescence analyses to detect (upper panels) Vps34 (green) and (middle panels) a phosphatidylinositol 3-phosphate bioprobe (GFP-EEA1-FYVE) in cardiac left ventricular sections from mice of the indicated genotypes. Representative images are shown. Blue, DAPI staining to detect nuclei. Arrowheads indicate GFP+ puncta. Scale bars: 10 μm. (Lower panels) GFP+ puncta were counted in 4 randomly chosen fields (10,000 μm2) for each sample (n = 4/group). **P < 0.01, 2-tailed Student’s t test. (B) Kaplan-Meier survival curves for mckCre-Vps34fl/fl (cVps34–/–) (n = 86), mckCre-Vps34fl/+ (cVps34+/–) (n = 61), and Vps34fl/fl (cVps34+/+) (n = 70) mice over the indicated period. All cVps34–/– mice were dead by P110. ***P < 0.001, log-rank test. (C) Heart weight to body weight ratios for individual cVps34+/+ (n = 40) and cVps34–/– (n = 39) mice over the indicated period. Linear regression lines are shown. ***P < 0.001, Pearson’s test. (D) Macroscopic views of hearts from cVps34+/+ and cVps34–/– mice at the indicated ages. Results are representative of at least 10 hearts examined per group. P, postnatal day. (E) Representative M-mode echocardiograms of cVps34+/+ and cVps34–/– mice (n = 6/group) at P80. (F) Electrocardiograms at P80 showing short runs of premature ventricular contraction (arrows), QT elongation, and bundle branch block (right panels) in a cVps34–/– mouse.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts